uniqueness [1:<1%) Renal: Renal insufficiency (3%; severe; creatinine clearance> <30 mL/minute) Respiratory: Dyspnea (1%)> <1%, (Limited to important or life threatening): Hypersensitivity reaction Warnings/Precautions Concerns related to adverse effects: Bleeding: Similar to other P2Y 12 antagonists, the use of cangrelor increases the risk of bleeding; however, due to the short elimination half-life, no antiplatelet effect is observed an hour after discontinuation. Hypersensitivity: Although rare, serious cases of hypersensitivity (eg, anaphylaxis, anaphylactic shock, bronchospasm, angioedema, stridor) have been reported with cangrelor. Concurrent drug therapy issues: Thienopyridines: If clopidogrel or prasugrel are administered prior to discontinuation of the cangrelor infusion, no antiplatelet effect will occur until the next dose is administered. Therefore, do not administer until after the cangrelor infusion is discontinued. Monitoring Parameters Monitor for signs/symptoms of bleeding. Pregnancy Risk Factor C Pregnancy Considerations Adverse events were observed in some animal reproduction studies. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Have patient report immediately to prescriber signs of bleeding (vomiting blood or vomit that looks like coffee grounds; coughing up blood; hematuria; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding) (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about cangrelor Side Effects During Pregnancy Drug Interactions Support Group 0 Reviews Add your own review/rating Drug class: platelet aggregation inhibitors Consumer resources Cangrelor Cangrelor Intravenous (Advanced Reading) Professional resources Cangrelor tetrasodium (AHFS Monograph) Other brands: Kengreal Related treatment guides Percutaneous Coronary Intervention> ] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Cangrelor Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Platelet aggregation inhibitors Related Drugs platelet aggregation inhibitors aspirin , clopidogrel , Plavix , Ecotrin , cilostazol Percutaneous Coronary Intervention Plavix , clopidogrel , bivalirudin , Integrilin , Angiomax , eptifibatide , More... among the finest
to admit Cangrelor expect
EmoticonEmoticon